Reply to the letter to the editor 'ALK FISH rearranged and amplified tumor with negative immunohistochemistry: A rare and challenging case concerning ALK status screening in lung cancer' by Uguen et al.

Annals of Oncology

Volumn 26, Issue 8, 2015, Pages 1802-

  Ilie, M ^a,b   Hofman, P ^a,b  

^a PASTEUR HOSPITAL   (France)

^b UNIVERSITY OF NICE SOPHIA ANTIPOLIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CRIZOTINIB; PROTEIN ALK; PROTEIN KINASE; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG; PROTEIN TYROSINE KINASE;

ALK GENE; CANCER INCIDENCE; CANCER SCREENING; DRUG EFFICACY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DOSAGE; GENE REARRANGEMENT; GENETIC ALGORITHM; HUMAN; IMMUNOHISTOCHEMISTRY; LETTER; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RARE DISEASE; TREATMENT RESPONSE; TUMOR GENE; ADENOCARCINOMA; ANTAGONISTS AND INHIBITORS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; LUNG TUMOR; MALE; PROCEDURES;

ADENOCARCINOMA; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84941642783     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv225     Document Type: Letter

References (6)

1. Uguen A, Talagas M, Andrieu-Key S et al. ALK FISH rearranged and amplified tumor with negative immunohistochemistry: a rare and challenging case concerning ALK status screening in lung cancer. Ann Oncol 2015; 26: 1514-1515.
2. Ilie MI, Bence C, Hofman V et al. Discrepancies between FISH and immunohistochemistry for assessment of the ALK status are associated with ALK 'borderline'-positive rearrangements or a high copy number: a potential major issue for anti-ALK therapeutic strategies. Ann Oncol 2015; 26: 238-244.
3. Wynes MW, Sholl LM, Dietel M et al. An International Interpretation Study using the ALK IHC antibody D5F3 and a sensitive detection kit demonstrates high concordance between ALK IHC and ALK FISH and between evaluators. J Thorac Oncol 2014; 9: 631-638.
4. von Laffert M, Warth A, Penzel R et al. Multicenter immunohistochemical ALK-testing of non-small-cell lung cancer shows high concordance after harmonization of techniques and interpretation criteria. J Thorac Oncol 2014; 9: 1685-1692.
5. Kelly RJ, Hillner BE, Smith TJ. Cost effectiveness of crizotinib for anaplastic lymphoma kinase-positive, non-small-cell lung cancer: who is going to blink at the cost? J Clin Oncol 2014; 32: 983-985.
6. de Figueiredo-Pontes LL, Wong DW, Tin VP et al. Identification and characterization of ALK kinase splicing isoforms in non-small-cell lung cancer. J Thorac Oncol 2014; 9: 248-253.